Madrigal Pharmaceuticals (YDO1) Stock Price & Analysis
YDO1 Stock Chart & Stats
- Day’s Range
- EUR 382.50 - EUR 388.40
- 52-Week Range
- EUR 347.50 - EUR 523.20
- Previous Close
- EUR 390.50
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 8.87B
- Enterprise Value
- EUR 15.16B
- Total Cash (Recent Filing)
- EUR 838.75M
- Total Debt (Recent Filing)
- EUR 347.75M
- Price to Earnings (P/E)
- ―
- Beta
- -0.24
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- -0.77
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Rezdiffra Adoption
Rezdiffra is demonstrating strong commercial traction, with rapid sales growth and a patient base that more than doubled year over year. Broad access, prescriber depth, adherence, and continued patient additions support a durable revenue expansion opportunity over the coming quarters.
Attractive Product Economics
The combination of substantial commercial revenue and exceptionally high gross margins indicates attractive unit economics for Rezdiffra. If the company can moderate commercial and research spending as sales scale, these economics provide a foundation for eventual operating leverage and stronger profitability.
Protected MASH Growth Platform
Long-dated intellectual-property protection supports Rezdiffra’s ability to remain a durable commercial foundation, while the expanding MASH pipeline creates avenues to broaden the franchise. Planned combination studies and additional assets could deepen the company’s market position over time.
Bears Say
Persistent Losses And Cash Burn
Despite the revenue ramp, Madrigal has not yet converted commercialization into positive operating or free cash flow. Continued cash consumption can restrict funding flexibility and may require the company to rely on its available resources until sales growth sufficiently exceeds operating and development costs.
Heavy Operating Investment
Madrigal is investing heavily in commercial expansion, endocrinology coverage, marketing, and pipeline development while still reporting losses. These costs may support future growth, but their continued increase raises the execution burden and delays the point at which strong gross margins translate into sustainable operating profitability.
Limited European Contribution
European launches and approvals have not yet translated into meaningful revenue because reimbursement access remains unresolved. This limits geographic diversification in the near term and leaves the business more dependent on continued U.S. execution while international market access develops more slowly than the product rollout.
Madrigal Pharmaceuticals News
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
Madrigal ($MDGL) announced an update on their ongoing clinical study. Madrigal Pharmaceuticals, Inc. is launching a Phase 2a study called “A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study” to
YDO1 FAQ
What was Madrigal Pharmaceuticals’s price range in the past 12 months?
What is Madrigal Pharmaceuticals’s market cap?
When is Madrigal Pharmaceuticals’s upcoming earnings report date?
How were Madrigal Pharmaceuticals’s earnings last quarter?
Is Madrigal Pharmaceuticals overvalued?
Does Madrigal Pharmaceuticals pay dividends?
What is Madrigal Pharmaceuticals’s EPS estimate?
How many shares outstanding does Madrigal Pharmaceuticals have?
What happened to Madrigal Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Madrigal Pharmaceuticals Stock Smart Score
Company Description
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Sibold
- Employees
- 915
- Website
- www.madrigalpharma.com
- Address
- 1001 Conshohocken State Road, West Conshohocken, PA, 19428, US
Madrigal Pharmaceuticals (YDO1) Earnings & Revenues
YDO1 Company Deck
YDO1 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by 71% year-over-year net sales growth, a patient base that more than doubled, progress past 50,000 patients, expanding market opportunity, encouraging real-world and clinical data, strengthened intellectual property, and a rapidly advancing pipeline. The main negatives were higher operating costs, a wider net loss, lower cash compared with year-end, negligible near-term European contribution due to reimbursement challenges, and continued uncertainty around the precise timing and event-rate dynamics of the F4-C trial. Highlights significantly outweighed the lowlights.
View all DE:YDO1 earnings summariesYDO1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |